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LETTER TO THE EDITOR
Reply to letter from Mr Benson and Professor Baum
Sir - The letter of Mr Benson and Professor Baum serves to
highlight the complexities associated with the pleiotropic
effects of the TGF-P family on tumour behaviour. We would
concur with much of the comment, but would like to add the
following detail and perspective.
It is clearly important to distinguish between changes in
the expression of TGF-13s which may occur with tumour
progression/stage of disease advancement and those which
may be associated with therapy. This is why, although we
have unpublished data relating to the effects of tamoxifen
treatment on the expression of TGF-P isoforms, these results
were not included in our paper (MacCallum et al., 1994)
which (i) describes the expression of the various isoforms of
TGF-P at the level of mRNA in a series of breast cancers
and (ii) makes a preliminary correlation with lymph node
involvement. The interesting finding from these studies was
that, despite a high incidence of TGF-3 expression of each
isoform (perhaps not surprising in view of the sensitivity of
the method employed), there were variations in the pattern of
mRNA expression between different tumours and this appar-
ently had some heirarchical order. Furthermore, the absence
(rather than the presence) of expression of one or more
TGF-P isoforms seemed to be associated with the spread of
tumour to regional lymph nodes. This observation, which has
now been confirmed in an extended series of 103 breast
cancers, would support the immunohistochemical study of
Walker and Dearing (1992), which indicated that TGF-P1
protein is associated with breast cancer spread to axillary
lymph nodes. Superficially these results appear at odds with
the concept that the TGF-,B family of growth factors are
negative regulators and, as such, might be expected to delay
advancement of disease. However, this would ignore the
accumulating evidence that both the expression of and res-
ponse to growth factors may change with tumour progres-
sion. Recently, Kerbel (1993) reviewed data that cytokines
which act negatively during the early stages of tumour
development may have no effect or may even function as
mitogens at more advanced stages of the same malignancy.
Melanoma was used as a paradigm but should this be true
for breast cancer the consequence could be that beneficial
responses to therapeutic intervention via cytokines may
depend upon whether tumour cells display an 'early' or 'late'
phenotype.
The other issue which has been raised by Mr Benson and
Professor Baum regards methods by which to assess growth
factor status. This is particularly relevant in the case of
TGF-P, for which mRNA and protein measurements may
not give concordant results, because of either post-
translational regulation or sequestration of the protein into a
different cellular compartment from which it was synthesised.
Ideally, one would like to measure each isoform at the level
of protein and mRNA and simultaneously determine cellular
distribution, but practical considerations are limiting. How-
ever, we have extended our work on mRNA by examining
tissue location using in situ hybridisation. Preliminary results
on a small series of tumours show differences in distribution
for the isoforms, TGF-,1I and -P2 being predominantly, but
not exclusively, associated with malignant epithelial cells,
while TGF-133 is largely restricted to vasculature. It is thus
interesting that immunohistochemical studies may produce
varying results on location of TGF-P protein depending on
the antibodies employed (McCune et al., 1992). Antibodies
against precursor protein produce staining in active tumour
epithelium, whereas those against secreted protein point to
localisation within the stromal compartment. This suggests
that TGF-,Bs which are synthesised within malignant
epithelium may after secretion be sequestered by stroma.
These considerations clearly illustrate the difficulties of
studying pleiotropic growth factors whose diversity resides
not only in isoform expression, post-translational
modification and compartmentalisation, but also in their
biological effects, which vary with development stage and cell
phenotype. There is no doubt that the definition of the role
of TGF-,B and similar cytokines in tumour behaviour will
demand careful study at the level of both mRNA and protein
and will encompass a variety of methodological approaches.
J. MacCallum
W.R. Miller
Imperial Cancer Research Fund,
Medical Oncology Unit,
Western General Hospital,
Edinburgh EH4 2XU, UK.
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